MEK inhibitors approved (in combination with a BRAF inhibitor) for therapy of metastatic melanoma with a BRAF V600E or V600K mutation are trametinib (in combination with dabrafenib), cobimetinib (in combination with vemurafenib), and binimetinib (in combination with encorafenib) [3••–4••, 9••]. This evidence concerns the gene BRAF and metastatic melanoma.